FDA concerns over sterility of products prompted a voluntary recall by Westborough, Mass.-based Ameridose of all its unexpired products in circulation, according to the American Society of Anesthesiology.
The FDA is currently conducting an inspection of the facility, and its preliminary findings have raised concerns about sterility assurance for all products produced and distributed by the facility.
The recall was not based on reports of patients with infections from Ameridose products, but rather a precaution since Ameridose shares common management with New England Compounding Center, the firm associated with the compounding drugs linked to the meningitis outbreak.
For a full list of Ameridose products, visit their site.
More Articles on Anesthesia:
Children Less Stressed Before Anesthesia Induction After Watching Videos
Significant Pain Relief for Abdominal, Pelvic Surgeries Provided by Dicolfenac
MedNet Hires Anesthesiologist Dr. Brian Waltmann as Medical Director
The FDA is currently conducting an inspection of the facility, and its preliminary findings have raised concerns about sterility assurance for all products produced and distributed by the facility.
The recall was not based on reports of patients with infections from Ameridose products, but rather a precaution since Ameridose shares common management with New England Compounding Center, the firm associated with the compounding drugs linked to the meningitis outbreak.
For a full list of Ameridose products, visit their site.
More Articles on Anesthesia:
Children Less Stressed Before Anesthesia Induction After Watching Videos
Significant Pain Relief for Abdominal, Pelvic Surgeries Provided by Dicolfenac
MedNet Hires Anesthesiologist Dr. Brian Waltmann as Medical Director